Data completeness
4/8 — Partial
SOAANZ (torsemide) by PharmaIN is clinical pharmacology mechanism of action micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of henle, where it inhibits the na/k/2ci-carrier system. First approved in 2021.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOAANZ (torsemide) is an oral loop diuretic approved in June 2021 that inhibits the Na/K/2Cl-carrier system in the thick ascending limb of the loop of Henle, promoting sodium, chloride, and water excretion. It is indicated for managing fluid overload and hypertension in patients with congestive heart failure, renal dysfunction, or hepatic cirrhosis. The drug achieves peak serum concentration within 1 hour with ~80% oral bioavailability and a 3.5-hour elimination half-life.
$0.005BPart D
Peak7.0 years to LOEProduct is at peak commercial stage with modest Medicare utilization, suggesting stable mid-sized brand team focused on market penetration rather than growth scaling.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Micropuncture studies in animals have shown that torsemide acts from within the lumen of the thick ascending portion of the loop of Henle, where it inhibits the Na/K/2CI-carrier system. Clinical pharmacology studies have confirmed this site of action in…
Worked on SOAANZ at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.